13 January 2015 / international
Debiopharm Diagnostics leads investment round in GenePOC with Emerillon Capital [Read more]
12 January 2015 / international
Debiopharm Group regains full rights to Alisporivir program [Read more]
08 January 2015 / international
FDA Grants Fast Track designation to Debiopharm Group’s antibiotic Debio 1450 [Read more]
18 November 2014
Debiopharm Group™ presents advances of two key oncology clinical programs at the 26th EORTC-NCI-AACR symposium in Barcelona [Read more]
07 October 2014
Debiopharm Group™ Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450, its Potent Anti-staphylococcal Agent [Read more]
30 September 2014
Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada [Read more]
18 December 2014
Debiopharm Investment, Ardian, Nixdorf Foundation and Bernis today acquire Eco Delta solar activities [Read more]
27 November 2014
Debiopharm Investment becomes a minority shareholder in Haut-Lac International Bilingual School in St-Légier (VD) [Read more]
17 November 2014
Coorpacademy, établi à l’EPFL et l’un des leaders des MOOCs à destination des entreprises, lève 3,2 millions d’euros auprès de Debiopharm Investment et du fonds français NextStage [Read more]
10 February 2015
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer [Read more]
21 November 2014
Preclinical activity of Debio 1347, an oral selective FGFR1, 2, 3 inhibitor, in models harboring FGFR alterations [Read more]
21 November 2014
Debio 1143 in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and platinum-refractory epithelial ovarian cancer (EOC). Preliminary results of a Phase I dose-escalat [Read more]
